Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × OTHER × pyrotinib × Clear all

Status

Unknown 39 Recruiting 29 Not yet recruiting 17 Active not recruiting 6 Terminated 1 Completed 1

Sponsor Class

INDUSTRY 5 OTHER_GOV 1 OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1

Interventions

Cyclophosphamide 791 Radiotherapy 715 Cisplatin 621 Gemcitabine 547 Carboplatin 511 Docetaxel 506 Paclitaxel 494 Bevacizumab 478 Fluorouracil 421 Rituximab 380 Oxaliplatin 374 Capecitabine 374 Surveys and Questionnaires 372 Doxorubicin 360 Dexamethasone 360 Etoposide 344 Irinotecan 323 Filgrastim 317 Cytarabine 314 pembrolizumab 264 Leucovorin 253 Melphalan 250 Magnetic Resonance Spectroscopy 242 fludarabine phosphate 240 Nivolumab 237 Peripheral Blood Stem Cell Transplantation 231 Blood Specimen Collection 231 Lenalidomide 230 Bortezomib 224 Methotrexate 223

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04756921 2021-02-16

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Fudan University

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡